British pharmaceutical giant AstraZeneca is increasing its focus on clinical trials and cancer-related projects within India, with the goal of accelerating the availability of its global products through technological advancements. Sanjeev Panchal, Managing Director and Country President of AstraZeneca Pharma India, highlighted the company's strategic initiatives in a recent interview.
AstraZeneca's global revenue reached around $45 billion last year, with approximately $10 billion allocated to research and development. This significant investment underscores the company's commitment to innovation and the development of new therapies.
Panchal emphasized the importance of policy support in India, where healthcare is largely an out-of-pocket expense for patients. The company aims to expand its clinical trial footprint in the country, recognizing the potential to improve access to cutting-edge treatments.
